Taking stock of the drug industry, from the lab to the medicine chestDecember 9, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Rachel Woolf for STAT STAT+ | This father built a gene therapy for his son. Now comes the harder part: saving others' children, too Terry Pirovolakis built a gene therapy to save his son from a rare disease. He has become the first stop and last hope for other desperate parents. By Jason Mast STAT+ | GSK myeloma medicine improves survival in trial, another step in the drug's revival GSK reported at #ASH2024 that its drug Blenrep helped patients live longer in a pivotal trial. By Andrew Joseph STAT+ | Biotech companies detail emerging efforts to ease 'conditioning' before genetic treatments Access to the near-curative treatments has been slowed by their high cost and the complicated procedures required to administer them. By Adam Feuerstein Arlene Ibarra for STAT STAT+ | Pfizer's abrupt withdrawal of sickle cell drug Oxbryta called 'tone deaf' at ASH conference Panelists at a STAT event said patients were despondent over how suddenly Oxbryta was pulled from the market and criticized the drug's rollout By Meghana Keshavan Trump suggests he shares some of RFK Jr.'s concerns about childhood vaccines Asked whether he wants childhood vaccines eliminated, President-elect Trump cited the rise in autism diagnoses: "What's happening?" he said By Matthew Herper More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments